C4 Therapeutics
Price & Volume
Stats
See moreOpen | $2.99 |
Previous Close | $2.95 |
Day Range | $2.98-$3.19 |
52W Range | $1.21-$3.82 |
Market Cap | $325M |
Shares Short | 21M |
Financials
See moreRevenue (12 Mos) | $35.9M |
Revenue Growth (YoY) | 112.8% |
Gross Profit (12 Mos) | $26.9M |
Diluted EPS | -$1.27 |
News
See moreYahoo Finance • 29 days ago
BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insight, Epidemiology, and Market Forecast Report 2022-2026 & 2026-2036 Featuring Novartis, Genentech, Fore Biotherapeutic, and C4 Therapeutics
Yahoo Finance • last month
C4 Therapeutics Enters Collaboration Agreement With Roche
Yahoo Finance • last month
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
Yahoo Finance • 3 months ago
Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential
About
CEO | Mr. Andrew J. Hirsch M.B.A. |
Address | 490 Arsenal Way, Watertown, MA, United States, 02472 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 104 |